a public good project by the
Synthesis
Company
of California

© 2026

Andrew Jack | doi.page

0 works0 citations0 h-index

Andrew Jack

University of Alberta(CA)

Publications by Year

Research Areas

Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Viral-associated cancers and disorders, Monoclonal and Polyclonal Antibodies Research, Multiple Myeloma Research and Treatments

Most-Cited Works

→ Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(2015)911 cited
→ Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network(2011)690 cited
→ Isolation and characterization of bone marrow multipotential mesenchymal progenitor cells(2002)618 cited
→ Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia(2008)602 cited
→ Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial(2006)592 cited
→ Rearrangement of MYC Is Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab(2010)549 cited

→ Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles(2013)

546 cited

→ Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK’s Haematological Malignancy Research Network(2015)419 cited

→ Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph)(2007)387 cited

→ Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial(2014)383 cited